KT-333 (5, 10, 15 and 45 mg/kg, iv.; once a week for two weeks) exhibits dose-dependent antitumor activity. Female NOD SCID mice with xenograft tumors of SU-DHL-1 administered with 5 mg/kg achieved 79.9% tumor growth inhibition (TGI), while those administered 10, 15, or 45 mg/kg experienced complete tumor regression, with these effects sustained until the end of the study[1].
KT-333 (10, 20 and 30 mg/kg, iv.; once a week for two weeks) exhibits dose-dependent antitumor activity. Female NOD SCID mice with xenograft tumors of SUP-M2 administered with 10 mg/kg achieved 83.8% tumor growth inhibition (TGI), while those administered 20 or 30 mg/kg experienced complete tumor regression, with these effects sustained until the end of the study[1].
